The international science journal “Nature” published in its special edition “Ra……
2024年3月
March 14th, 2024
Observation period completed for primary endpoint – Phase II study in patients with recurrent high-grade meningioma
Our company provides the boron drug for BNCT (Boron Neutron Capture Therapy), w……
March 4th, 2024
Interim Analysis Results of Post-Marketing Surveillance of Our Drug Product published ― Safety of Boron Neutron Capture Therapy with Borofalan(10B) and Its Efficacy on Recurrent Head and Neck Cancer
The results regarding safety and effectiveness of our product Borofalan(10B), u……
